Karmustin Pliva (Carmustine)

Carmustine belongs to the nitrosourea class of alkylating agents. It covalently binds to DNA, primarily at the O6‑guanine position, and creates interstrand cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in fast‑growing tumour cells, and it can cross the blood‑brain barrier, making it effective for central nervous system cancers.

The dosage of Karmustin Pliva is individualized by the treating oncologist based on the specific cancer type, patient weight, renal and hepatic function, and the overall chemotherapy regimen. The prescriber determines the appropriate amount, infusion rate, and schedule in accordance with established clinical guidelines and the patient’s tolerance.

Carmustine is classified as contraindicated for use during pregnancy because it can cross the placenta and cause fetal harm, including teratogenic effects. Breastfeeding is also discouraged, as the drug may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To request Karmustin Pliva, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assistance with import documentation.

Compared with other alkylating agents, Carmustine offers the advantage of crossing the blood‑brain barrier, making it particularly useful for central nervous system tumours. However, its toxicity profile, especially pulmonary and hematologic effects, can be more pronounced than some alternatives. Treatment decisions balance efficacy, tumour location, and patient tolerance, often incorporating Carmustine into combination regimens to enhance overall response.

Karmustin Pliva should be stored at controlled room temperature, typically below 25 °C. Keep the vials in their original packaging, protect them from light, moisture and extreme temperature fluctuations. Do not freeze the product. Follow any additional handling instructions provided by the supplier to maintain drug stability until administration.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting. The infusion rate and total dose are determined by the prescribing oncologist, and the drug is usually given over a period of minutes to hours, depending on the treatment protocol and patient tolerance.

The most serious risks include pulmonary toxicity such as interstitial pneumonitis or fibrosis, severe myelosuppression leading to infection or bleeding, and the potential development of secondary malignancies. Patients should be monitored closely for respiratory symptoms, blood count changes, and any signs of new cancers during and after therapy. Prompt medical attention is required if serious adverse events occur.

Carmustine is contraindicated in individuals with known hypersensitivity to nitrosoureas or any component of the formulation. It should also be avoided in patients with severe pulmonary disease, uncontrolled infections, or those who are pregnant or breastfeeding. Clinicians must assess each patient’s medical history, organ function and concomitant medications before initiating therapy.